Latrepirdine
- Generic Name
- Latrepirdine
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3
- CAS Number
- 3613-73-8
- Unique Ingredient Identifier
- OD9237K1Z6
- Background
Latrepirdine has been investigated for the treatment of Alzheimer's Disease and Huntington's Disease.
An Extension of the CONCERT Protocol (DIM18)
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 672
- Registration Number
- NCT01152216
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 362
- Registration Number
- NCT01085266
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
Phase 3
Terminated
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT01066546
- Locations
- 🇺🇸
Pfizer Investigational Site, Delray Beach, Florida, United States
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
Phase 1
Completed
- Conditions
- Alzheimer's DiseaseHuntington's Disease
- Interventions
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT00990613
- Locations
- 🇺🇸
Pfizer Investigational Site, Kalamazoo, Michigan, United States
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
Phase 1
Completed
- Conditions
- Alzheimer's DiseaseHuntington Disease
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00988624
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Phase 1
Completed
- Conditions
- Alzheimer's DiseaseHuntington's Disease
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2013-04-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00975481
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
Phase 3
Terminated
- Conditions
- Moderate to Severe Alzheimer
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT00954590
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 649
- Registration Number
- NCT00939783
- Locations
- 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
Phase 1
Completed
- Conditions
- Alzheimer's DiseaseHuntington's Disease
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2009-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00931073
- Locations
- 🇺🇸
Pfizer Investigational Site, Kalamazoo, Michigan, United States
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT00920946
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath